Multiple indirect metabolic and immunological pathways

The term "Multiple indirect metabolic and immunological pathways" refers to a classification used for therapeutic agents that do not have a single, well-defined molecular target such as a specific receptor or enzyme [1]. Instead, these agents exert their effects through a complex web of indirect interactions that influence the body's metabolic state and immune system [2]. This is common for complex biologicals, probiotics, and phenotypic drug candidates where the clinical benefit is observed, but the exact molecular choreography is multifaceted or not yet fully elucidated [1,3]. Because these agents act on systemic pathways, they are often used to treat chronic inflammatory conditions, metabolic syndrome, or gut-related disorders [2]. Understanding these pathways requires a systems biology approach rather than traditional reductionist pharmacology, as the therapeutic outcome is the result of network-level modulation [1,3]. References: [1] Moffat, J. G., et al. (2017). "Opportunities and challenges in phenotypic drug discovery." Nature Reviews Drug Discovery. [2] Hill, C., et al. (2014). "The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic." Nature Reviews Gastroenterology & Hepatology. [3] National Institutes of Health (NIH). (2023). "Glossary of Common Site Terms." ClinicalTrials.gov.

Other names

Unknown / multiple indirect metabolic and immunological pathwaysIndirect metabolic pathwaysIndirect immunological pathwaysNon-specific mechanism of actionPhenotypic mechanism

Modulation of systemic physiological processes through indirect interactions with multiple metabolic and immune signaling networks, often without a primary high-affinity binding site on a single protein [1,2].